As hep C revenues decline, investors ask: Who is Gilead?
As sales of its hit Hep C drugs decline, Gilead faces an uncertain future. Where to next for a company defined by one blockbuster franchise?
Gilead to pay Merck $2.54B in largest-ever patent infringement case
A federal jury has awarded $2.54 billion in royalties to Merck, ruling against Gilead in a monumental patent infringement case involving two blockbuster hepatitis C drugs. The kicker? The judge has the power to triple that figure.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Morning Read: Merck is giving Gilead’s Hepatitis C drug Sovaldi a run for its money
Also, a reverse merger by Synta Pharmaceuticals and Madrigal Pharmaceuticals will create a company that focuses on non-alcoholic steatohepatitis and Kaiser Permanente has launched a biobank to develop new diagnoses and treatment plans.
Massive cancer philanthropy fraud, a global backlash again Sovaldi cost (Morning Read)
Sovaldi, cancer theft, J&J makes move in Hepatitis C, and tough days for health insurance companies in Oregon - and more.
There’s a life-saving hepatitis C drug (But you may not be able to afford it)
There’s a new drug regimen being touted as a potential cure for a dangerous liver virus that causes hepatitis C. But it costs $84,000 — or $1,000 a pill. And that price tag is prompting outrage from some consumers and a scramble by insurers to figure out which patients should get the drug —and who pays for it. […]